<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747109</url>
  </required_header>
  <id_info>
    <org_study_id>RC12_0178</org_study_id>
    <nct_id>NCT01747109</nct_id>
  </id_info>
  <brief_title>Benefits of Optiflow® Device for Preoxygenation Before Intubation in Acute Hypoxemic Respiratory Failure : The PREOXYFLOW Study</brief_title>
  <acronym>PREOXYFLOW</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Controlled, Parallel-group, Open Label Trial Evaluating Benefits of Nasal High Flow Therapy (HFT) in Preoxygenation Before Tracheal Intubation in Acute Hypoxemic Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oro-tracheal intubation in intensive unit care(ICU) in acute hypoxemic respiratory failure&#xD;
      after crash induction remains a critical event.&#xD;
&#xD;
      The aim of this study is to determine whether Nasal High Flow Therapy (HFT) Optiflow ® is&#xD;
      more efficient than the face mask for preoxygenation before orotracheal intubation after&#xD;
      crash induction in acute hypoxemic respiratory failure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be designed as followed : Patients will be randomized in 2 groups&#xD;
      :&quot;PREOXYFLOW&quot; or &quot;STANDARD FACE MASK&quot;.&#xD;
&#xD;
      Patients randomized in &quot;PREOXYFLOW&quot; group will received a four minutes preoxygenation period&#xD;
      with Nasal High Flow Therapy (HFT) (60 l/mn FIO2 = 1) before orotracheal intubation under&#xD;
      laryngoscopy after crash induction. Patients randomized in &quot;STANDARD FACE MASK&quot; group will&#xD;
      received a four minutes preoxygenation period with standard face mask (15 l/mn) before&#xD;
      orotracheal intubation under laryngoscopy after crash induction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to determine whether Optiflow® used during the preoxygenation period before orotracheal intubation after crash induction is more efficient than standard face mask.</measure>
    <time_frame>4 minutes</time_frame>
    <description>This outcome will be assessed from the beginning of the preoxygenation period to the end of orotracheal intubation by monitoring the pulse oxymetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of preoxygenation</measure>
    <time_frame>4 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in side effects incidence related to intubation</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Organ failure in the 5th day</measure>
    <time_frame>at day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in morbi-mortality during the Intensive Care Unit stay.</measure>
    <time_frame>until day 28 OR, if patient still in the intensive care unit (ICU) at Day 28, until discharge of ICU</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Acute Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>PREOXYFLOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized in &quot;PREOXYFLOW&quot; group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STANDARD FACE MASK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized in &quot;STANDARD FACE MASK&quot; group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PREOXYFLOW</intervention_name>
    <description>Patients randomized in &quot;PREOXYFLOW&quot; group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction</description>
    <arm_group_label>PREOXYFLOW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>STANDARD FACE MASK</intervention_name>
    <description>Patients randomized in &quot;STANDARD FACE MASK&quot; group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)</description>
    <arm_group_label>STANDARD FACE MASK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults older than 18 years regardless of the gender&#xD;
&#xD;
          -  Acute hypoxemic respiratory failure defined as :&#xD;
&#xD;
        Respiratory rate &gt; 30/mn AND Hypoxemia with SpO2 &lt;90% with oxygen supply &gt; FiO2 0,5 AND&#xD;
        PaO2/FiO2 &lt;300 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to oro-tracheal intubation&#xD;
&#xD;
          -  Intubation without anesthetic delivery&#xD;
&#xD;
          -  Intubation during cardiac arrest&#xD;
&#xD;
          -  Asphyxia with immediate intubation needed&#xD;
&#xD;
          -  Nasopharyngeal obstacle with contraindication to use Optiflow device&#xD;
&#xD;
          -  Patients with a documented Cormack IV exposition before inclusion&#xD;
&#xD;
          -  Protected adult&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lack of consent&#xD;
&#xD;
          -  Patient already enrolled in an other randomized study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nantes Universitary Hospital, medical intensive care unit</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angers Universitary Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brest Universitary Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Roche/Yon Hospital</name>
      <address>
        <city>La Roche/Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier University hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes Universitary Hospital, surgical intensive care unit</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute hypoxemic respiratory failure</keyword>
  <keyword>Preoxygenation</keyword>
  <keyword>Crash induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

